Product Details
| Product Name:
RG13022 |
CAS No.:
136831-48-6 |
| Purity:
98.38% |
Supply Ability:
10g |
| Release date:
2024/11/19 |
Product Introduction
Bioactivity
| Name | RG13022 |
| Description | RG13022 (Tyrphostin RG13022) is a tyrosine kinase inhibitor; inhibits the autophosphorylation reaction of the EGF receptor (IC50: 4 μM). |
| Cell Research | 40 mM stock solutions of RG13022 is made in 100% DMSO and diluted with the culture medium before addition to the cells. MH-85 cells and HER 14 cells are plated in culture medium in the presence or absence of increasing concentrations of RG-13022 or RG-14620 for 10 days. At the end of culture, the cells are fixed with 4% (v/v) formaldehyde and stained with hematoxylin. Numbers of colonies including more than 20 cells in each well are counted under the microscope[1]. |
| In vitro | RG13022 suppresses EGF-stimulated cancer cell proliferation and inhibits EGF receptor autophosphorylation in immunoprecipitates (IC50: 4 μM) in a cell-free reaction. It inhibits colony formation (IC50: 1 μM) and DNA synthesis (IC50: 3 μM) in HER 14 cells stimulated by 50 ng/mL EGF, dose-dependently. Additionally, RG13022 inhibits growth stimulated by insulin, insulin-like growth factor I, insulin-like growth factor II, or transforming growth factor alpha. It completely blocks estrogen-stimulated phosphorylation of the EGF receptor and estrogen-induced cell proliferation, indicating that functioning TK pathways are essential for estrogen action. |
| In vivo | RG13022 suppresses tumor growth and extends the lifespan of tumor-bearing nude mice. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 50 mg/mL (187.76 mM)
|
| Keywords | HER1 | Inhibitor | RG13022 | EGFR | Tyrphostin RG-13022 | inhibit | ErbB-1 | Tyrphostin RG 13022 | RG-13022 | Epidermal growth factor receptor |
| Inhibitors Related | Osimertinib | Lidocaine Hydrochloride hydrate | Lapatinib | Afatinib Dimaleate | Erlotinib hydrochloride | Erlotinib | Neratinib | Chalcone | Osimertinib mesylate | Genistein | Khellin | Gefitinib |
| Related Compound Libraries | Anti-Lung Cancer Compound Library | Reprogramming Compound Library | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Kinase Inhibitor Library | Tyrosine Kinase Inhibitor Library | JAK-STAT Compound Library | Inhibitor Library | Bioactive Compounds Library Max | Anti-Cancer Active Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
-
CAS:104121-92-8
$2340.00 / 10mg
-
CAS:154447-36-6
$34.00 / 5mg
-
Recommended supplier
| Product name |
Price |
|
Suppliers |
Update time |
|
|
$/ |
|
Anhui Ruihan Technology Co., Ltd
|
2023-08-21 |
United States